Rapamycin With Grapefruit Juice for Advanced Malignancies

NCT ID: NCT00375245

Last Updated: 2014-01-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-09-30
• Study Completion Date: 2012-05-31

Brief Summary

The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice.

Conditions

Tumors; Neoplasm Metastasis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Rapamycin + Grapefruit juice

Group Type: EXPERIMENTAL

Rapamycin (sirolimus)

Intervention Type: DRUG

Weekly oral doses, dose is assigned at the time of study entry

Grapefruit Juice

Intervention Type: OTHER

Daily oral doses starting during the second week on study.

Interventions

Rapamycin (sirolimus)

Weekly oral doses, dose is assigned at the time of study entry

Intervention Type: DRUG

Grapefruit Juice

Daily oral doses starting during the second week on study.

Intervention Type: OTHER

Other Intervention Names

Rapamune

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
• Patients with hematologic malignancies (lymphoma, multiple myeloma and chronic lymphocytic leukemia (CLL) only) are eligible to participate in the phase IB portion of the trial only.
• At least 4 weeks since prior chemotherapy or radiation therapy
• Aged 18 years or older
• ECOG performance status 0-2
• Life expectancy of greater than 3 months.
• Normal organ and marrow function:

• No transfusions of packed red blood cells within 1 week of starting treatment
• Leukocytes greater or equal to 3,000/μL

** White blood cell (WBC) greater or equal to 1,500/μL for patients with hematologic malignancies

• Absolute neutrophil count (ANC) greater or equal to 1,500/μL

** ANC greater or equal to 1,000/μL for patients with hematologic malignancies

• Platelets (PLT) greater or equal to 100,000/μL

** PLT greater or equal to 50,000/μL for patients with hematologic malignancies

• Total bilirubin within normal institutional limits
• AST (SGOT) and ALT (SGPT) less than or equal to 2.5 times institutional upper limit of normal
• Serum triglycerides less than or equal to 500 mg/dl
• Creatinine within normal institutional limits OR creatinine clearance greater or equal to 60 mL/min for patients with creatinine levels above institutional normal
• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence)
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

• Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
• May not be receiving any other investigational agents.
• Uncontrolled brain metastases or malignancy. Cannot be receiving enzyme-inducing anticonvulsants.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to rapamycin
• Gastrointestinal malabsorption syndromes, partial small bowel obstruction, or any illness that would interfere with the ability to absorb oral medications.
• Uncontrolled intercurrent illness
• Severe immunodeficient states (as judged by the treating physician)
• Pregnant women are excluded from this study; breastfeeding should be discontinued.
• HIV-positive patients receiving combination antiretroviral therapy are excluded.
• Concurrent use of ketoconazole, cyclosporine, tacrolimus, diltiazem, and rifampin with rapamycin is not permissible. The concurrent use of calcium channel blockers, terfenadine, astemizole, cisapride, propafenone, cyclosporine, midazolam, triazolam, quinidine, or theophylline with grapefruit juice is not permissible.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Chicago

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ezra W Cohen, MD

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Locations

University of Chicago Hospitals

Chicago, Illinois, United States

Countries

United States

References

Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009 Feb;9(2):247-61. doi: 10.1586/14737140.9.2.247.

Reference Type: DERIVED

PMID: 19192962 (View on PubMed)

Other Identifiers

14435B

Identifier Type: -

Identifier Source: org_study_id